Table 2 Summary measures and comparison of baseline patient characteristics between the different C1M, C3M and RF subgroups

N

474

237

237

118

237

237

118

94

380

198

240

234

118

Gender (%)

87.8

79.7*

74.6**

84.0

83.5

83.1

84.0

83.7

84.0

87.1

80.3*

77.1*

Age, years

53.8 (12.1)

53.7 (12.6)

54.1 (13.0)

53.8 (12.2)

53.4 (12.5)

53.2 (11.2)

54.9 (12.7)

53.4 (12.2)

54.4 (11.5)

53.7 (12.2)

53.8 (12.5)

54.0 (12.2)

BMI, kg/cm²

28.2 (6.3)

27.9 (6.2)

28.6 (6.4)

28.8 (6.6)

27.9 (6.1)

28.6 (6.4)

28.9 (6.0)*

28.7 (7.1)

28.1 (6.1)

28.2 (5.8)

27.9 (6.1)

28.5 (6.5)

28.6 (6.8)

Disease duration, years

8.6 (8.2)

8.9 (8.8)

8.4 (7.7)*

8.0 (7.3)

8.1 (8.5)

9.2 (7.9)*

9.2 (8.0)*

7.2 (8.9)

9.0 (8.0)**

9.7 (7.4)****

8.3 (8.3)

9.0 (8.1)

8.7 (7.4)

C1M, nmol/mL

103 (80)

47 (16)

159 (779)****

216 (76)****

72 (49)

134 (92)****

157 (103)****

96 (84)

105 (79)

106 (79)

56 (25)

150 (88)****

193 (94)****

C3M, nmol/mL

34.1 (15)

29.7 (12.5)

38.4 (15.9)****

42.4 (15.2)****

23.6 (4.6)

44.6 (14.3)****

53.7 (15.6)****

27.7 (10.7)

35.6 (15.4)***

40.9 (17.8)****

28.3 (10.3)

39.9 (16.7)****

44.4 (18.4)****

RF, Units/mL

230 (400)

226 (370)

233 (428)****

263 (497)

117 (174)

342 (515)****

489 (651)****

10 (4)

284 (430)****

494 (514)****

153 (228)

308 (509)****

356 (579)****

CRP, mg/dL

15.6 (21.1)

6.1 (8.8)

25.0 (25.2)****

39.0 (29.0)****

8.5 (10.6)

22.6 (26.1)****

30.9 (31.0)****

12.2 (19.2)

16.4 (21.5)**

18.7 (22.3)****

3.8 (2.3)

27.9 (24.7)****

42.9 (27.2)****

DAS

5.7 (0.9)

5.4 (0.8)

6.1 (0.8)****

6.4 (0.8)****

5.5 (0.8)

6.0 (0.9)****

6.2 (0.9)****

5.6 (0.8)

5.8 (0.9)*

5.9 (1.0)**

5.3 (0.7)

6.2 (0.8)****

6.5 (0.8)****

SJC28

12.0 (5.5)

11.7 (5.5)

12.3 (5.6)**

13.2 (5.9)*

11.1 (5.0)

12.9 (5.9)**

13.2 (5.9)**

11.0 (5.3)

12.2 (5.6)*

12.7 (6.0)

11.2 (5.2)

12.9 (5.8)**

13.1 (5.8)**

TJC28

15.7 (6.2)

15.2 (6.0)

16.1 (6.3)

16.8 (6.4)*

15.1 (5.6)

16.2 (6.6)

16.8 (6.8)*

15.1 (6.1)

15.8 (6.2)

16.2 (6.6)

15.0 (5.8)

16.3 (6.5)*

16.7 (6.5)*

HAQ

1.6 (0.6)

1.5 (0.6)

1.6 (0.6)**

1.8 (0.6)****

1.5 (0.6)

1.6 (0.6)**

1.8 (0.6)***

1.4 (0.6)

1.6 (0.6)***

1.7 (0.6)***

1.4 (5.8)

1.7 (0.6)****

1.8 (0.6)****

HAQ PAIN

61.2 (19.2)

57.9 (18.0)

64.5 (19.9)*

69.8 (18.0)****

59.5 (18.1)

62.9 (20.1)*

64.7 (19.7)**

60.1 (19.4)

61.5 (19.2)

62.4 (19.6)

56.5 (18.3)

66.1 (19.0)****

69.7 (18.6)****

Evaluators global assessment

61.7 (16.1)

59.7 (16.2)

63.8 (15.8)*

67.0 (15.0)***

59.9 (16.2)

63.6 (15.8)*

64.9 (14.8)*

59.7 (16.6)

62.2 (16.0)

63.9 (14.7)

59.3 (16.2)

64.2 (15.7)**

66.4 (14.8)***

Patients global assessment

60.2 (19.7)

57.1 (18.8)

63.3 (20.1)*

69.2 (17.8)****

58.3 (18.6)

62.0 (20.6)*

64.6 (19.4)**

60.1 (18.9)

60.2 (19.9)

60.2 (21.1)

55.8 (19.1)

64.7 (19.3)****

68.4 (19.1)****

MTSS

46.8 (63.2)

42.1 (61.2)

51.4 (64.9)*

58.0 (68.6)**

40.8 (59.3)

52.7 (66.4)*

66.8 (75.6)***

25.2 (48.7)

52.1 (65.2)****

62.2 (71.6)****

35.2 (53.4)

58.6 (70.0)***

66.3 (69.9)****

JSN

24.0 (30.9)

21.5 (30.0)

26.5 (31.7)*

29.1 (33.0)**

21.0 (29.5)

27.0 (32.0)*

33.7 (35.9)***

12.9 (23.9)

26.7 (31.8)****

31.8 (34.4)****

18.1 (23.3)

30.2 (33.9)****

33.7 (32.9)****

ERN

22.8 (33.7)

20.6 (32.8)

24.9 (34.5)

28.9 (37.3)*

19.8 (31.0)

25.7 (36.0)

33.1 (41.3)**

12.3 (25.4)

25.3 (35.0)***

30.4 (39.2)****

17.2 (28.4)

28.4 (37.6)****

32.6 (38.6)****